Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDiaceutics Regulatory News (DXRX)

Share Price Information for Diaceutics (DXRX)

Share Price is delayed by 15 minutes
Get Live Data
138.00    -3.50 (-2.47%)
Bid:
136.00
Ask:
140.00
Spread: 4.00 (2.941%)
Market Cap: £116.79m
DXRX Live PriceLast checked at - London Stock Exchange

Intraday Diaceutics Share Chart

Poster presentation at ESMO

30 Sep 2019 08:01

RNS Number : 0424O
Diaceutics PLC
30 September 2019
Ā 

Diaceutics PLC

("Diaceutics" or the "Company")

Ā 

Poster presentation at ESMO

Ā 

Diaceutics PLC (AIM: DXRX), the data analytics and implementation services company which services the global pharmaceutical industry, announces it will present a poster at the 2019 European Society of Medical Oncology Congress ("ESMO") in Barcelona today. ESMO will run from 27 September - 1 October 2019.

Ā 

ESMO is the most influential oncology meeting in Europe, in partnership with the EACR (European Association for Cancer Research). The ESMO Congress is the appointment in Europe for clinicians, researchers, patient advocates,Ā journalists and the pharmaceutical industry from all over the world to get together, learn aboutĀ the latest advances in oncology and translate science into better cancer patient care.

Ā 

The Company will present a poster entitled "Known and unknown gene fusion detection capabilities of solid tumour laboratories conducting next generation sequencing in 6 countries". The Poster focusses on the current next generation sequencing ("NGS") capabilities in solid tumour oncology laboratories to detect unknown gene fusions, and concludes that labs in the EU have not kept up with the technical advances in NGS testing due to a lack of sufficient funding, which may lead to missed opportunities for improved treatment for patients.

Ā 

The poster can be viewed via this link once it has been presented:Ā 

Ā 

http://www.rns-pdf.londonstockexchange.com/rns/0424O_1-2019-9-29.pdf

Ā 

Enquiries:

Ā 

Diaceutics PLC

www.diaceutics.com

Peter Keeling, Chief Executive Officer

via Walbrook PR

Philip White, Chief Financial Officer

Ā 

Ā 

Ā 

Cenkos Securities plc (Nominated adviser and broker)

+44 (0) 20 3861 6630

Callum Davidson / Giles Balleny

Ā 

Michael Johnson (Sales)

Ā 

Ā 

Ā 

Walbrook PR

Tel: +44 (0)20 7933 8780 or diaceutics@walbrookpr.com

Anna Dunphy

Mob: +44 (0)7876 741 001

Paul McManus

Mob: +44 (0)7980 541 893

Ā Ā Ā Ā Ā Ā 

Ā 

Ā 

Ā 

About Diaceutics

Diaceutics PLC is a leading diagnostics data analytics and implementation services provider for global pharmaceutical companies. The Company, quoted on the Alternative Investment Market (AIM) of the London Stock Exchange, is enabling Pharma to accelerate their market penetration and achieve a better return on precision medicine therapies by helping them to revolutionise patient testing. By generating insights from its data lake of clinical laboratory testing data and other data, Diaceutics helps Pharma understand and leverage the diagnostic landscape through initiatives that improve patient testing, leading to better treatment outcomes. The Company works with more than 30 global pharmaceutical companies across hundreds of precision medicine projects. The Company employs a leading global group of experts from the laboratory, diagnostic and pharmaceutical industries. www.diaceutics.com

Ā 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
Ā 
END
Ā 
Ā 
NRACKCDDKBKDPCB
Date   Source Headline
19th Jun 20207:00 amRNSHolding(s) in Company
11th Jun 20202:00 pmRNSExercise of warrant
11th Jun 20207:00 amRNSPlacing of £20.5 million
19th May 20202:29 pmRNSResult of AGM
19th May 20207:00 amRNSAGM Statement
18th May 20207:00 amRNSDiagnostic network for precision medicine update
5th May 202011:22 amRNSDirector’s Shareholding - PCA Dealing
29th Apr 20207:00 amRNSCancer testing & diagnosis suffers sharp downturn
23rd Apr 20207:00 amRNSPosting of Annual Report and Notice of AGM
6th Apr 20207:00 amRNSIssue of Share Options
19th Mar 20207:00 amRNSBelfast investor presentation
17th Mar 20209:05 amRNSSecond Price Monitoring Extn
17th Mar 20209:00 amRNSPrice Monitoring Extension
16th Mar 202011:05 amRNSSecond Price Monitoring Extn
16th Mar 202011:00 amRNSPrice Monitoring Extension
16th Mar 20207:00 amRNSFinal Results
12th Mar 20202:24 pmRNSPrivate investor briefing
27th Feb 20207:00 amRNSNotice of Results
17th Feb 20207:00 amRNSBelfast investor presentation
6th Feb 20207:00 amRNSGrowth & Innovation Forum 2020
17th Jan 20202:53 pmRNSHolding(s) in Company
13th Jan 20209:05 amRNSSecond Price Monitoring Extn
13th Jan 20209:00 amRNSPrice Monitoring Extension
13th Jan 20207:00 amRNSYear-End Trading Update
25th Nov 20197:00 amRNSPresentation at AICon 2019
24th Oct 20197:00 amRNSPresentation at Big Data Belfast
21st Oct 20197:00 amRNSPharma Precision Medicine Readiness Report
10th Oct 20197:00 amRNSWorkshop presentation at EORTC
30th Sep 20198:01 amRNSPoster presentation at ESMO
23rd Sep 20197:00 amRNSDublin investor presentation
9th Sep 20197:00 amRNSHalf-year Report
8th Aug 20197:00 amRNSAppointment of Head of Global Data
8th Aug 20197:00 amRNSNotice of Results
8th Jul 20197:00 amRNSTrading update
17th Jun 20197:00 amRNSInvestment in data lake
28th May 20197:00 amRNSInvestor presentation
25th Mar 20194:29 pmRNSHolding(s) in Company
25th Mar 20197:00 amRNSHolding(s) in Company
21st Mar 20192:05 pmRNSSecond Price Monitoring Extn
21st Mar 20192:00 pmRNSPrice Monitoring Extension
21st Mar 20197:00 amRNSAdmission to AIM & First Day of Dealings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.